 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Aprea Therapeutics
APRE
conference date: August 12, 2025, press release only
Aprea Therapeutics Cancer Therapy Platform Is Promising [July 21, 2020 at Seeking Alpha]
Aprea Therapeutics (APRE) is a clinical-stage biotechnology company specializing in therapies for cancers with TP53 mutations.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BLRX |
| BMY |
| BOLD |
| CCCC |
| CLDX |
| CBIO |
| BMY |
| FATE |
| GILD |
| GLYC |
| ILMN |
| INO |
| IONS |
| LGND |
| MCHP |
| MRNA |
| REGN |
| RNA |
| RXRX |
| SAGE |
| SANA |
| SUPN |
| VRTX |
| VSTM |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2025 William P. Meyers